Tolerizing allografts of pluripotent stem cells
First Claim
Patent Images
1. A method for preparing cells for therapeutic use, comprising:
- a) differentiating human pluripotent stem (hPS) cells into a first cell population; and
b) differentiating human pluripotent stem (hPS) cells into a second cell population;
wherein the first cell population is MHC compatible with the second cell population, and whereupon administration of the first population to an individual renders the individual immunotolerant to the second cell population.
1 Assignment
0 Petitions
Accused Products
Abstract
This disclosure provides a system for overcoming HLA mismatch between an allograft derived from stem cells, and a patient being treated for tissue regeneration. A state of specific immune tolerance is induced in the patient, by administering a population of tolerizing cells derived from the stem cells. This allows the patient to accept an allograft of differentiated cells derived from the same source. This invention is important because it allows a single line of stem cells to act as a universal donor source for tissue regeneration in any patient, regardless of tissue type.
20 Citations
20 Claims
-
1. A method for preparing cells for therapeutic use, comprising:
-
a) differentiating human pluripotent stem (hPS) cells into a first cell population; and
b) differentiating human pluripotent stem (hPS) cells into a second cell population;
wherein the first cell population is MHC compatible with the second cell population, and whereupon administration of the first population to an individual renders the individual immunotolerant to the second cell population. - View Dependent Claims (2, 3, 4, 5, 7)
-
-
6. A method for preparing a first cell population that renders an individual to whom it is administered immunotolerant to a second cell population, comprising differentiating human pluripotent stem (hPS) cells into a mixed cell population, and enriching from the mixed population cells that express CD34, T-cell receptor, HLA Class II, CMRF-44, CMRF-56, DEC-205, S100, or CTLA-4.
-
8. A combination of pharmaceutical compounds, comprising in separate containers:
-
a) a first cell population that has been differentiated from human pluripotent stem (hPS) cells into a phenotype that renders a subject to whom it is administered immunotolerant to a second cell population; and
b) the second cell population that is MHC compatible with the first cell population. - View Dependent Claims (9, 10, 11, 12, 13)
-
-
14. A method for reconstituting cellular function in an individual, comprising administering to the individual a first cell population and a second cell population, both differentiated from human pluripotent stem (hPS) cells, wherein the first cell population is MHC compatible with the second cell population,
whereupon administration of the first cell population renders the individual immunotolerant to the second cell population; - and
whereupon administration of the second cell population reconstitutes the cellular function. - View Dependent Claims (15, 16, 17, 18, 19)
- and
-
20. A method of preparing an individual for therapy to reconstitute their cellular function, comprising administering to the individual a first cell population differentiated from human pluripotent stem (hPS) cells, thereby rendering the individual immunotolerant to a second cell population also differentiated from hPS cells that is MHC compatible with the first cell population, wherein the therapy comprises administering to the individual the second cell population, thereby reconstituting the cellular function in the individual.
Specification